Matthias Aizenberg

The historical classification of the PVT1 locus as a non-coding region has been overturned by evidence showing it produces functional proteins that dictate the survival of malignant cells. For decades, the oncology community has viewed the MYC gene as the most frustrating obstacle in cancer

A major challenge in pharmaceutical development is the high failure rate of programs that stall because a target protein’s structure cannot be mapped. For many years, the pharmaceutical industry relied heavily on physical laboratory experiments that were both time-consuming and prone to human

A record 383 vials of LYMPHIR were ordered in July, establishing a new performance benchmark for the company’s expanded 29-member nationwide sales infrastructure. This milestone represents a significant pivot for Citius Pharmaceuticals as it transitions from a clinical-stage entity into a

Regulatory shifts are forcing health service providers to move away from passive privacy policies toward active notification systems, such as website pop-ups, that inform users of data collection at the point of entry. This transition comes at a critical juncture where the boundary between seeking

The move away from carbon offsetting signals a maturation in corporate sustainability where physical decarbonization takes precedence over accounting-based neutrality claims. This evolution reflects a growing understanding that the pharmaceutical industry must confront its environmental impact

The transformation of discarded medical waste into a sophisticated fleet of microscopic couriers capable of delivering life-saving gene therapies directly to tumors represents a fundamental shift in how medicine interacts with the human body. In the current landscape of 2026, the primary challenge

The healthcare landscape is currently undergoing a radical transformation as major institutions seek to internalize the engine of innovation rather than simply consuming third-party solutions. The rebranding of Rex Health Ventures marks a significant strategic move to align corporate venture

The persistent search for a definitive treatment for Duchenne muscular dystrophy (DMD) has entered a sophisticated new era where regenerative medicine takes center stage against genetic muscle wasting. The FDA has recently cleared an expansion for a Phase 2 clinical trial that evaluates the safety

Dramatically expanding the top of the discovery funnel ensures that the handful of compounds selected for synthesis possess significantly higher predicted potency and solubility. The pharmaceutical industry is currently witnessing a fundamental shift in how drug candidates are identified and

Transitioning from an experimental tool to a foundational administrative asset, ambient voice technology is now being utilized across the NHS to automate the labor-intensive process of clinical documentation and coding. This shift follows pivotal guidance issued in the summer of 2026 by the